Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
190 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Psoriatic Arthritis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H1 2015', provides an overview of the Psoriatic Arthritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Psoriatic Arthritis Overview 8 Therapeutics Development 9 Pipeline Products for Psoriatic Arthritis - Overview 9 Pipeline Products for Psoriatic Arthritis - Comparative Analysis 10 Psoriatic Arthritis - Therapeutics under Development by Companies 11 Psoriatic Arthritis - Therapeutics under Investigation by Universities/Institutes 15 Psoriatic Arthritis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Psoriatic Arthritis - Products under Development by Companies 20 Psoriatic Arthritis - Products under Investigation by Universities/Institutes 23 Psoriatic Arthritis - Companies Involved in Therapeutics Development 24 AbbVie Inc. 24 AbGenomics International, Inc. 25 Alder Biopharmaceuticals Inc. 26 Amgen Inc. 27 Avesthagen Limited 28 Biocon Limited 29 Bristol-Myers Squibb Company 30 Celgene Corporation 31 Celltrion, Inc. 32 Coherus BioSciences, Inc. 33 Covagen AG 34 Eli Lilly and Company 35 Epirus Biopharmaceuticals, Inc. 36 Genor BioPharma Co., Ltd. 37 Inbiopro Solutions Pvt. Ltd. 38 Innovent Biologics, Inc. 39 Johnson & Johnson 40 Kineta, Inc. 41 Mabion SA 42 Momenta Pharmaceuticals, Inc. 43 Novartis AG 44 Oncobiologics, Inc. 45 Panacea Biotec Limited 46 Pfizer Inc. 47 Sandoz International GmbH 48 Swedish Orphan Biovitrum AB 49 Therapeutic Proteins International, LLC 50 UCB S.A. 51 Psoriatic Arthritis - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Target 53 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 abatacept (recombinant) - Drug Profile 61 AbGn-168H - Drug Profile 64 ABT-122 - Drug Profile 66 adalimumab biosimilar - Drug Profile 68 adalimumab biosimilar - Drug Profile 69 adalimumab biosimilar - Drug Profile 70 adalimumab biosimilar - Drug Profile 71 adalimumab biosimilar - Drug Profile 72 adalimumab biosimilar - Drug Profile 73 adalimumab biosimilar - Drug Profile 74 adalimumab biosimilar - Drug Profile 75 adalimumab biosimilar - Drug Profile 76 anakinra (recombinant) - Drug Profile 77 apremilast - Drug Profile 78 bimekizumab - Drug Profile 81 brodalumab - Drug Profile 82 clazakizumab - Drug Profile 84 COVA-322 - Drug Profile 86 dalazatide - Drug Profile 87 etanercept biosimilar - Drug Profile 89 etanercept biosimilar - Drug Profile 90 etanercept biosimilar - Drug Profile 91 etanercept biosimilar - Drug Profile 92 etanercept biosimilar - Drug Profile 93 etanercept biosimilar - Drug Profile 94 etanercept biosimilar - Drug Profile 95 etanercept biosimilar - Drug Profile 96 golimumab - Drug Profile 97 golimumab biosimilar - Drug Profile 100 guselkumab - Drug Profile 101 IBI-303 - Drug Profile 104 IBPM-004AM - Drug Profile 105 IBPM-005IX - Drug Profile 106 infliximab biosimilar - Drug Profile 107 infliximab biosimilar - Drug Profile 109 infliximab biosimilar - Drug Profile 110 infliximab biosimilar - Drug Profile 111 infliximab biosimilar - Drug Profile 112 INV-17 - Drug Profile 113 itolizumab - Drug Profile 114 ixekizumab - Drug Profile 116 Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - Drug Profile 117 secukinumab - Drug Profile 118 tofacitinib - Drug Profile 122 Psoriatic Arthritis - Recent Pipeline Updates 126 Psoriatic Arthritis - Dormant Projects 176 Psoriatic Arthritis - Discontinued Products 177 Psoriatic Arthritis - Product Development Milestones 178 Featured News & Press Releases 178 Appendix 186 Methodology 186 Coverage 186 Secondary Research 186 Primary Research 186 Expert Panel Validation 186 Contact Us 186 Disclaimer 187
List of Tables Number of Products under Development for Psoriatic Arthritis, H1 2015 12 Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Development by Companies, H1 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Late Stage Development, H1 2015 19 Comparative Analysis by Clinical Stage Development, H1 2015 20 Comparative Analysis by Early Stage Development, H1 2015 21 Comparative Analysis by Unknown Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2015 27 Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2015 28 Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 29 Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2015 30 Psoriatic Arthritis - Pipeline by Avesthagen Limited, H1 2015 31 Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2015 32 Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2015 33 Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2015 34 Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2015 35 Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2015 36 Psoriatic Arthritis - Pipeline by Covagen AG, H1 2015 37 Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2015 38 Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 39 Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2015 40 Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 41 Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2015 42 Psoriatic Arthritis - Pipeline by Johnson & Johnson, H1 2015 43 Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2015 44 Psoriatic Arthritis - Pipeline by Mabion SA, H1 2015 45 Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 46 Psoriatic Arthritis - Pipeline by Novartis AG, H1 2015 47 Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2015 48 Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2015 49 Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2015 50 Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2015 51 Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2015 52 Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2015 53 Psoriatic Arthritis - Pipeline by UCB S.A., H1 2015 54 Assessment by Monotherapy Products, H1 2015 55 Number of Products by Stage and Target, H1 2015 57 Number of Products by Stage and Mechanism of Action, H1 2015 59 Number of Products by Stage and Route of Administration, H1 2015 61 Number of Products by Stage and Molecule Type, H1 2015 63 Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2015 129 Psoriatic Arthritis - Dormant Projects, H1 2015 179 Psoriatic Arthritis - Discontinued Products, H1 2015 180
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
